Vion Pharmaceuticals Announces FDA Lift Of Clinical Hold On Phase III Study Of Cloretazine(R) (VNP40101M) And Cytarabine In Relapsed AML

VION PHARMACEUTICALS, INC. (Nasdaq: VION) announced that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold on the Phase III trial (Vion Study CLI-037) of its lead anti-cancer agent, Cloretazine(R) (VNP40101M), in combination with cytarabine in relapsed acute myelogenous leukemia (AML).

More: continued here

Filed under: Lymphoma / Leukemia on January 9th, 2008